IDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care with intelligently designed precision combination therapies. Inspired by a few curative combination regimens in cancer and the successful drug cocktails purposely engineered in other disease areas such as cystic fibrosis and antivirals, IDRx aims to address the limitations of today’s precision cancer medicines with highly -selective, purposely -designed drug combinations to help more patients achieve prolonged, durable responses to therapy earlier in the course of their disease. Founded in 2022, IDRx’s leadership team has extensive experience in drug development, and collectively has been involved in the discovery, development and commercialization of more than 10 approved drugs.
Location: United States, Massachusetts, Plymouth
Member count: 11-50
Total raised: $122M
Founded date: 2022
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 06.08.2022 | Series A | $122M | - | finsmes.co... |
Mentions in press and media 3
| Date | Title | Description | Source |
| 29.11.2022 | Pitchbook’s Emerging Technology Indicator Reports Shows Q3 D... | Pitchbooks new Emerging Technology Indicator report shows that Q3 deal value is down.getty Pitchboo... | forbes.com... |
| 02.08.2022 | IDRx Raises $122M in Series A Financing | IDRx, Inc., a Plymouth, MA-based clinical-stage biopharmaceutical company dedicated to transforming ... | finsmes.co... |
| - | Aiming to bring drug combos into earlier lines of cancer the... | A precision medicine is only as good as its target. While targeted therapies now address many types ... | medcitynew... |